NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma
D Daley, VR Mani, N Mohan, N Akkad… - Journal of Experimental …, 2017 - rupress.org
The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA) is
characterized by immune tolerance, which enables disease to progress unabated by …
characterized by immune tolerance, which enables disease to progress unabated by …
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models
Y Zhu, BL Knolhoff, MA Meyer, TM Nywening, BL West… - Cancer research, 2014 - AACR
Cancer immunotherapy generally offers limited clinical benefit without coordinated
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …
strategies to mitigate the immunosuppressive nature of the tumor microenvironment. Critical …
Tumor cell–derived IL1β promotes desmoplasia and immune suppression in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy typified by a highly
stromal and weakly immunogenic tumor microenvironment that promotes tumor evolution …
stromal and weakly immunogenic tumor microenvironment that promotes tumor evolution …
[HTML][HTML] Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of …
J Yang, Q Zhang, J Wang, Y Lou, Z Hong, S Wei… - …, 2022 - thelancet.com
Background Pancreatic ductal adenocarcinoma (PDAC) has little response to immune
checkpoint inhibitors. An in-depth understanding of the immune microenvironment from a …
checkpoint inhibitors. An in-depth understanding of the immune microenvironment from a …
[HTML][HTML] Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination …
Background Complex tumor and immune microenvironment render pancreatic ductal
adenocarcinoma (PDAC) resistant to immune checkpoint inhibitors (ICIs). Therefore, a …
adenocarcinoma (PDAC) resistant to immune checkpoint inhibitors (ICIs). Therefore, a …
[HTML][HTML] RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance and
immunotherapeutic resistance. We discovered upregulation of receptor-interacting …
immunotherapeutic resistance. We discovered upregulation of receptor-interacting …
[HTML][HTML] Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic …
X Zhang, M Lao, J Xu, Y Duan, H Yang… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Methods Tumor necrosis factor receptor 2 (TNFR2) was analyzed via immunohistochemistry,
immunofluorescence, western blotting, and ELISAs. The in vitro mechanism that TNFR2 …
immunofluorescence, western blotting, and ELISAs. The in vitro mechanism that TNFR2 …
[HTML][HTML] Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing
Pancreatic ductal adenocarcinoma (PDA) is an inherently immune cell deprived tumor,
characterized by desmoplastic stroma and suppressive immune cells. Here we …
characterized by desmoplastic stroma and suppressive immune cells. Here we …
A functional role for Nlrp6 in intestinal inflammation and tumorigenesis
The nucleotide-binding oligomerization domain-like receptor (NLR) family member, Nlrp6,
has been implicated in inflammasome signaling to activate caspase-1, which is essential for …
has been implicated in inflammasome signaling to activate caspase-1, which is essential for …
Receptor-interacting protein kinase 2 is an immunotherapy target in pancreatic cancer
W Sang, Y Zhou, H Chen, C Yu, L Dai, Z Liu, L Chen… - Cancer discovery, 2024 - AACR
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy because of
its aggressive nature and the paucity of effective treatment options. Almost all registered …
its aggressive nature and the paucity of effective treatment options. Almost all registered …